Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    NIAID Creating Quantitative Viral Outgrowth Assay Service

    By Global Biodefense StaffJuly 29, 2014
    Quantitative Viral Outgrowth Assay
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    The Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID) supports basic research as well as pre-clinical and clinical evaluation of various HIV eradication strategies.

    In order to evaluate the effectiveness of these strategies at clearing the latent reservoir, a reproducible assay capable of quantifying latent HIV is crucial. The best characterized assay today is the QVOA (Quantitative Viral Outgrowth Assay), also known as IUPM assay (Infectious Units Per Million) (Siliciano and Siliciano 2005), performed on highly purified resting CD4+ T cells under conditions that reverse latency and induce replication of HIV.

    QVOA measurements require large volumes of blood, are expensive, tedious, and labor intensive and therefore not the assay of choice for many laboratories conducting HIV eradication research.

    NIAID has a requirement to provide the QVOA as a service to the HIV research community. This service will allow standardized QVOA measurements so that unbiased comparisons between different eradication strategies can be achieved. Widespread use of the assay will raise the standards for latent HIV detection and reduce the need for surrogate, less accurate assays, presently used by some laboratories.

    The scope of the work includes:

    • Performance of the QVOA
    • Development of alternative assays to the QVOA. The aim will be the development of assays that are less costly, require smaller amounts of blood, and can be completed more rapidly, while maintaining or exceeding the sensitivity of the QVOA.
    • Training investigators to perform the QVOA at the Respondent’s site

    The contract will be for one base year and up to seven option years. In addition, NIAID may exercise options for an increased level of effort that may result from unanticipated increases in demand for the services supported by the base requirements of this contract.

    Proposals will be evaluated for technical approach, scientific and technical personnel, project management, resources, facilities, equipment, and capability to address options.

    Further details are available under Solicitation Number: NIAID-DAIDS-NIHAI2013184. Responses are due August 14, 2014.

    HIV Request for Proposals
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleMan-Portable Radiological Detection System (MRDS)
    Next Article DARPA BRICS Synthetic Biology Proposers’ Conference

    Related Stories

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    APHIS Announces Funding for Tribes to Support Animal Disease Preparedness and Response

    October 24, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.